Potential drug-drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross-sectional study of the national covid cohort collaborative (N3C).

Xuya Xiao Hemalkumar B MehtaJill CurranBrian T GaribaldiG Caleb Alexandernull null

Published in: Pharmacotherapy (2023)

One in six of individuals receiving nirmatrelvir/ritonavir were at risk of a potential moderate or severe DDI, underscoring the importance of clinical and pharmacy systems to mitigate such risks.

Keyphrases

human health
quality improvement
coronavirus disease
sars cov
antiretroviral therapy
risk assessment
early onset
high intensity
risk factors
emergency department
drug induced
climate change
newly diagnosed